Thursday, 16 January 2020

Bone Scan Market 2019 Global Size, Share, Top Leaders, Historical Analysis, Sales Revenue, Opportunities, Development Status, Competitive Landscape and Regional Forecast to 2023


Bone Scan Market Information: By Product (Radiopharmaceuticals, Imaging Devices), Application (Fractures, Arthritis, Paget's Disease of Bone, Cancer Originating in Bone), End User (Hospitals, Clinics, Diagnostic Centers) - Global Forecast till 2023
Market Synopsis of the Global Bone Scan Market
According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.
The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.
A bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.

Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.
Key Players in the Global Bone Scan Market   
·         Siemens (U.S.)
·         Hitachi, Ltd. (Japan)
·         Carestream Health, Inc. (U.S.)
·         Samsung Electronics Co., Ltd. (South Korea)
·         Toshiba Corporation. (Japan)
·         Koninklijke Philips N.V. (Netherlands)
·         General Electric Company (U.S.)
Segments of the Global Bone Scan Market
The global bone scan market is segmented on the basis of product, indication, device, and end user.
On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.
On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis
The Americas lead the global bone scan market owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.
Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.
The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.
Browse More Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Posted by at No comments:
Labels: ,

Silent Heart Attack Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023


Silent Heart Attack Market Research Report: By Diagnosis (CT, MRI, ECG, Blood Tests), Treatment (Medications, Coronary Angioplasty And Stenting, Coronary Artery Bypass Surgery), End User (Hospital, Clinic, Diagnostic Center) - Global Forecast till 2023                                                                                                                          
Market Synopsis of the Global Silent Heart Attack Market
The market for silent heart attack is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing demand for diagnosis devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of market. However, high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market.
The global silent heart attack market is expected to grow at a CAGR of 5.7% during the forecast period.
According to the Center for Disease Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. Cardiovascular diseases, and diabetes are increasing the economic burden of various developing and developed nations across the globe.
Silent heart attack usually does not have any symptoms. The patient may experience chest pain, shortness of breath and cold sweats. It is mostly misunderstood as indigestion, nausea, and other common diseases. The silent heart attack is usually caused due to various factors such as smoking or chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity. Risk of silent heart attack increases with an increase among the diabetic population and people addicted to smoking. Various imaging tests such as Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI), electrocardiogram, echocardiogram, blood tests, and others.
Segments                                                                                                                                            
The global silent heart attack market is segmented on the basis of diagnosis, indication, devices, and end user.
On the basis of diagnosis, market is segmented into cardiac computerized tomography, magnetic resonance imaging, electrocardiogram, echocardiogram, blood tests, and others.
On the basis of indication, the market is segmented into medications, coronary angioplasty and stenting, coronary artery bypass surgery, and others.
On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Key Players in the Global Silent Heart Attack Market   
Some of the key players in this market are Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland) and F. Hoffmann-La Roche Ltd (Switzerland).
Regional Analysis of the Global Silent Heart Attack Market                 
America accounts for the largest market for the silent heart attack. Increasing prevalence of cardiovascular diseases, and diabetes is the major driving factor for the growth of the market. According to Center of Diseases Control and Prevention (CDC), 9.3% of the total America population is suffering from diabetes. Increasing diabetic and obese population, rising demand for the better treatment for the diseases and well developed infrastructure has provided fuel for the growth of the market. North America accounts for the major share in the American silent heart attack market.
Europe accounts for the second largest market due to a well-developed healthcare sector, continuously increasing patient population and high healthcare expenditure. Additionally, increasing prevalence of diabetes in the European Union (EU) also fuels the market growth. Germany, U.K and France hold the first, second and third position in the market.
Asia Pacific is expecting the fastest growth for this market. Increasing prevalence of cardiovascular diseases and rapid developments in the healthcare infrastructure are the major driving factors for the growth of the market. India and China are the two major regions with the highest contribution to the market growth owing to the highest diabetic population, and increasing presence of heart attack among these patients. Additionally, rising geriatric population further drive the growth of the market.
In the Middle East & Africa, the market is expected to show steady growth due to the evolving healthcare system, and increasing demand for diagnostic and treatment services. The Middle East is the major contributor for the market which is driven by presence of well developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth due to limited development in the field of medical science and presence of poor economic conditions in various developing regions of Africa.
Top 5 Reasons to Get this Report:
Company profiling with detailed strategies, financials, and recent development activities
Market Strategic Business Influence Data
Market Research Future recommendations in key business segments based on the market estimations
Market share analysis of the top industry players
Market forecasts for a minimum of 5 years of all the mentioned segments, Trends and the regional markets With SWOT Analysis
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Posted by at No comments:
Labels:

Brain Dead Diagnosis and Treatment Industry Overview, Trends and Market Growth Analysis Research Report 2023

Brain Dead Diagnosis & Treatment Research Report: By Diagnosis Type (Physical Examination, Blood Test, Brain Scans) Brain Scans (CT, MRI, EEG) Treatment (Medical Treatment) End User (Hospitals & Clinics, Research Laboratories) - Global Forecast till 2023
Market Scenario
The increasing incidence of accidents and brain injury is leading to shift from treatment to oragn donation procedures are some factors responsible for the growth of the global brain dead diagnosis and treatment market.
A brain-dead patient is supposed to have no clinical evidence of brain function upon physical examination. The examination exhibits no cranial nerve reflexes and no response to pain. The reflexes include no spontaneous respirations, oculocephalic reflex, pupillary response (fixed pupils), corneal reflex, and no response to the caloric reflex test. According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
It is of utmost important to distinguish brain death and other states that may be difficult to differentiate from brain death, such as alcohol intoxication, chronic vegetative states, barbiturate overdose, hypoglycemia, hypothermia, coma, and sedative overdose. Few comatose patients can recover to pre-coma level of functioning, and some patients with severe irreversible neurological dysfunction will nonetheless retain some lower brain functions, such as spontaneous respiration, despite the losses of both cortex and brain stem functionality in case of anencephaly. However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global market of brain dead diagnosis and treatment is expected to grow at a CAGR of approximately 7% during the forecast period 2017-2023.
Intended Audience
  • Brain Dead Diagnosis and Treatment Suppliers
  • Brain Dead Diagnosis and Treatment Trends
  • Brain Dead Diagnosis and Treatment Manufacturers
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities
Segmentation
The brain dead diagnosis and treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, transcranial doppler ultrasonography
On the basis of treatment, it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.
Key Players in the Global Brain Dead Diagnosis and Treatment Market    
Some of key the players in the Global Brain dead diagnosis and Treatment Market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others
Regional Analysis
The global brain dead diagnosis and treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global brain dead diagnosis and treatment market owing to the increasing healthcare expenditure. In the United States, if the patient is at or near death, the hospital must notify a transplant organization of the person's details and maintain the patient while the patient is being evaluated for suitability as a donor. The patient is kept on ventilator support until the organs have been surgically removed. Furthermore, increased R&D activities and the concentration of major companies have fueled the growth of the market in this region.
Europe holds the second position in the global brain dead diagnosis & treatment market owing to the government support for research & development and availability of funds for research. For instace, in countries such as Spain, Finland, Poland, Wales, Portugal, and France, everyone is automatically an organ donor after diagnosis of death on legally accepted criteria, although some jurisdictions such as Singapore, Spain, Wales, France, Czech Republic and Portugal allow opting out of the system. Elsewhere, consent from family members or next-of-kin may be mandatory for organ donation.
Asia Pacific is the fastest growing brain dead diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries such as New Zealand, Australia, drivers are asked upon application if they wish to be registered as an organ donor are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region. 
Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Posted by at No comments:

Coma Diagnosis and Treatment Market Growth Opportunities, Analysis and Forecasts Report 2019-2023

Coma Diagnosis & Treatment Market Research Report: By Types (Toxic-Metabolic Encephalopathy, Anoxic Brain Injury), Diagnosis (Physical Examination, Brain Scans) Treatment (Medical Treatment), End User (Hospitals & Clinics) - Global Forecast till 2023
Market Scenario
Coma refers to a state of unconsciousness in which a patient remains unresponsive to anything around them for a prolonged period of time. Depending on the severity of the coma, patient may require life-saving resuscitative measures and once the patient is medically stable, treatments can be used to treat original problem that is causing the coma.
There is no particular treatment that can cause someone to come out of a coma and treatments can prevent further physical and neurological damage. However depending on the cause of a coma, patient who are continuosly in this state for more than one year are extremely unlikely to awaken.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the Coma Diagnosis and Treatment Market Size. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
Over the last decade, the number of hospitals has increased to a great extent, which has influenced the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth.
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global coma diagnosis & treatment market is expected to grow at a CAGR of ~7.1% during the forecast period 2017-2023. 
Key Players
  • GE Healthcare (U.S.)
  • Siemens Healthcare(U.S.)
  • Philips Healthcare (U.S.)
  • Carestream Health (U.S.)
  • Electrical Geodesics Inc. (U.S.)
  • Masimo Corporation (U.S.)
  • Hologic (U.S.)
  • Shimadzu Corporation (Japan)
  • Toshiba Medical Systems Corporation (Japan)
  • Fujifilm Holdings (Japan)
  • Nihon Kohden Corporation (Japan)
  • Esaote (Italy)

Regional Analysis
Asia Pacific is the fastest growing coma diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  
The Americas dominate the global coma diagnosis & treatment market owing to well-developed technology, increasing patient population for brain disorder, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Europe holds the second position in the global coma diagnosis & treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
Segmentations
The global coma diagnosis & treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of diagnosis it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of the type, it is segmented into toxic- metabolic encephalopathy, anoxic brain injury, persistent vegetative state, locked-in syndrome, and brain death.  
On the basis of treatment it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.
Posted by at No comments:

Neuropathology Market 2019 Global Key Vendors Analysis, Revenue, Trends & Forecast to 2023

Neuropathology Market Research Report By Diagnosis (Biopsy, Body Fluids, Peripheral Blood Smears, others), Application (Cerebral Hypoxia & Stroke, Perinatal Disorders, CNS Infections, Demyelinative Diseases, others), End User– Global Forecast till 2023
Market Synopsis of the Global Neuropathology Market
Neuropathology pertains to the aliment of nerves reculting in pain and numbness of the limbs and it is gaining prominence in this market. The increasing incidence of musculoskeletal conditions and technological advancements in medical diagnostic devices are some factors responsible for the growth of the global neuropathology market size.
The number of patients suffering from cerebrovascular disorders has increased rapidly and has reached an all-time high in the past few years. There has been a significant rise in the number of surgeries associated with the treatment of such disorders. As the neurosurgeries and spinal surgeries are very critical, continuous monitoring during the whole procedure proves to be beneficial as the information about the electrical signals in brain and the nerves can be obtained in real time.
The Global market of Neuropathology is expected to grow at a CAGR of approximately 6% during the forecast period 2019-2023.
Biopsies primarily consist of the skin. The recently developed neuropathy test, the epidermal nerve fiber density testing (ENFD) in which the nerve fibers of the skin is analysed by performing a  punch skin biopsy to identify small fiber neuropathies. This pathology test is becoming available in selected labs as well as a few universities; it replaces the traditional sural nerve biopsy test and is less invasive. It is used to identify painful small fiber neuropathies.
According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases. Many healthcare professionals have started using these diagnostics techniques, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for Neuropathology.
Key Players
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.
  • ARUP Laboratories
  • Therapath LLC
  • Abbott Laboratories
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Hoffmann-La Roche Ltd.
  • Sakura Finetek USA Inc.
  • Danaher Corporation
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.N
  • NeoGenomics Laboratories
Segmentation
The Neuropathology is segmented on the basis of diagnosis test, application, and end-users.
On the basis of diagnostic test, the market is segmented into the biopsy, body fluids, peripheral blood smears, tissue resections, and others 
The biopsy sub-segment is divided into Epidermal nerve fiber density testing (ENFD), Sural nerve biopsy test, bone-marrow biopsies, lymph-node biopsies and others
On the basis of product, the application market is segmented into cerebral hypoxia and stroke, perinatal disorders, CNS infections, demyelinative diseases, brain tumors, neurodegenerative diseases, inherited metabolic disorders, peripheral neuropathy, and myopathology
On the basis of end-user, the market is segmented into hospitals, clinics, research centers and others.
Regional Analysis
The Global Neuropathology Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global neuropathology market owing to the increasing healthcare expenditure in North America since 2016. U.S. has some of the best hospitals in the world with state of the art infrastructure. Most of the hospitals and their neurology departments are well equipped with the equipment that is required for the working of the neuropathology techniques. Various organizations and private companies are engaged in the activities of spreading awareness about the benefits of the neuropathology test among common people through various educational and marketing ways. As a result, huge numbers of people are opting for the neuropathology tests as a point of care. The country has been developing number of academic courses to develop skilled personnel in the neuropathology field over the years. Hence the availability of the neuropathology specialists in North American countries is high.
Europe is the second largest market for neuropathology market. For Europe, the neuropathology market including the brain tumors market is regarded as a strong competitive market. European countries are now making efforts in promoting the benefits of the intraoperative neurophysiological monitoring services. Patient friendly healthcare and insurance policies are making a positive impact on the people taking medical assistance.
Asia Pacific is the fastest growing region over the forecast period. The healthcare spending in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
he connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease disorder market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
  • Abbott Laboratories
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • Pfizer
  • AutoImmune Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Biogen
  • LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Posted by at No comments:

Connective Tissue Disease Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 – 2023


Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2023
Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease disorder market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
·         Abbott Laboratories
·         Bayer AG
·         F. Hoffmann-La Roche Ltd
·         Pfizer
·         AutoImmune Inc.
·         Johnson & Johnson
·         Amgen Inc.
·         AstraZeneca
·         Eli Lilly and Company
·         Biogen
·         LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Posted by at No comments:
Subscribe to: Posts (Atom)